Here, we show that H2AFJ differs from other H2A subfamily members in that it is highly expressed by mesenchymal-type GBM tissues and serves as a predictive factor for TMZ effectiveness in GBM patients. The gene discussed is H2AJ; the disease is glioblastoma.